Nat Rev Cardiol:PCI术后死亡原因分析

2014-05-13 坞霜降 dxy

经皮冠状动脉介入治疗(PCI)临床应用已有40余年时间。美国梅约诊所回顾性研究显示,PCI的应用减少了患者的心血管死因,但是越来越多患者死于非心血管原因。 梅约诊所Rajiv Gulati医生表示,“为了更好的分配临床资源来减少PCI术后的长期死亡率,我们需要准确掌握患者的死因、特因死亡率时间趋势以及造成这些现象的内在原因。” 研究选取了自1997年至2008年19077例PCI术后存活的患者

经皮冠状动脉介入治疗(PCI)临床应用已有40余年时间。美国梅约诊所回顾性研究显示,PCI的应用减少了患者的心血管死因,但是越来越多患者死于非心血管原因。

梅约诊所Rajiv Gulati医生表示,“为了更好的分配临床资源来减少PCI术后的长期死亡率,我们需要准确掌握患者的死因、特因死亡率时间趋势以及造成这些现象的内在原因。”

研究选取了自1997年至2008年19077例PCI术后存活的患者。其中37%的患者在一段时间后死亡。98.1%患者的死因已被掌握。按照患者PCI手术的时间,患者分为3组,每组间隔5年。

统计结果显示每五年PCI患者的死亡率降幅约为33%.调整基线变量后,心血管原因死亡率降幅为50%,而非心血管原因死亡率无明显变化。除心衰外,心肌梗死及心脏骤停引起的死亡比例随时间降低,而因癌症或慢性疾病的死亡比例随时间增大。

Rajiv Gulati认为心血管原因死亡数降低可能是由于“二级预防治疗方面的改进、PCI技术或PCI术者水平”造成的。研究者声称,“在现有防治心血管原因死亡的基础上,如果我们对非心血管并发症进行全面治疗,那么死亡率会得到进一步改善。”

对于PCI的死亡风险率较高的患者亚群(例如ST段抬高心肌梗死患者或伴有外周血管疾病的患者),Rajiv Gulati研究团队正着手对其特因死亡率时间趋势及其内在原理开展研究。研究者也会利用研究数据建立预测相关特因死亡率的风险模型。


原始出处:

Gregory B. Lim.Causes of death after PCI.Nature Reviews Cardiology 11, 186 (2014) doi:10.1038/nrcardio.2014.20 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903505, encodeId=5e671903505ba, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Tue Nov 25 11:12:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633804, encodeId=9f8c163380455, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Mar 31 13:12:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880058, encodeId=da491880058e4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 20 22:12:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781671, encodeId=06311e81671fa, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 23 19:12:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486406, encodeId=8a50148640652, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu May 15 00:12:00 CST 2014, time=2014-05-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1903505, encodeId=5e671903505ba, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Tue Nov 25 11:12:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633804, encodeId=9f8c163380455, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Mar 31 13:12:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880058, encodeId=da491880058e4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 20 22:12:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781671, encodeId=06311e81671fa, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 23 19:12:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486406, encodeId=8a50148640652, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu May 15 00:12:00 CST 2014, time=2014-05-15, status=1, ipAttribution=)]
    2015-03-31 zxl736
  3. [GetPortalCommentsPageByObjectIdResponse(id=1903505, encodeId=5e671903505ba, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Tue Nov 25 11:12:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633804, encodeId=9f8c163380455, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Mar 31 13:12:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880058, encodeId=da491880058e4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 20 22:12:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781671, encodeId=06311e81671fa, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 23 19:12:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486406, encodeId=8a50148640652, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu May 15 00:12:00 CST 2014, time=2014-05-15, status=1, ipAttribution=)]
    2014-10-20 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1903505, encodeId=5e671903505ba, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Tue Nov 25 11:12:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633804, encodeId=9f8c163380455, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Mar 31 13:12:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880058, encodeId=da491880058e4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 20 22:12:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781671, encodeId=06311e81671fa, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 23 19:12:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486406, encodeId=8a50148640652, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu May 15 00:12:00 CST 2014, time=2014-05-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1903505, encodeId=5e671903505ba, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Tue Nov 25 11:12:00 CST 2014, time=2014-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633804, encodeId=9f8c163380455, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Mar 31 13:12:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880058, encodeId=da491880058e4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 20 22:12:00 CST 2014, time=2014-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781671, encodeId=06311e81671fa, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 23 19:12:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486406, encodeId=8a50148640652, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu May 15 00:12:00 CST 2014, time=2014-05-15, status=1, ipAttribution=)]

相关资讯

Am J Cardiol:伴CABG病史患者的CTO病变 PCI复合方法可行

美国一项研究表明,与不伴冠脉旁路移植术(CABG)病史的患者相比,通过复合方法(“hybrid” crossing algorithm)对伴CABG病史患者的慢性完全闭塞病变实施经皮冠脉介入(CTO PCI)的成功率稍低,但并发症发生率相似。论文于4月2日在线发表于《美国心脏病学杂志》(Am J Cardiol)。 此项研究共纳入496例接受CTO PCI治疗的序贯性患者,并对伴和不伴CABG病

Am J Cardiol:GPI不改善STEMI预后

法国一项研究表明,在计划行直接经皮冠脉介入(PPCI)治疗的STEMI患者中,起病后12小时内应用糖蛋白IIb/IIIa抑制剂(GPI)未能改善梗死相关动脉(IRA)开放和院内严重不良心脏事件。论文于5月5日在线发表于《美国心脏病学杂志》(Am J Cardiol)。 此项前瞻性研究共纳入2052例STEMI患者;受试者均在起病后12小时内于重症监护急救车(MICU)接受治疗,并且计划行PPCI

Am J Cardiol:PCI房颤患者,口服抗凝路漫漫

一项日本研究显示,真实世界中行PCI的房颤患者口服抗凝使用不足且抗凝强度往往不够,接受口服抗凝的患者长期使用双联抗血小板治疗(DAPT)未降低卒中发生率。论文4月25日在线发表于《美国心脏病学杂志》。 在CREDO-Kyoto登记队列-2中,研究者从12716例接受首次经皮冠脉介入术(PCI)的患者中识别出1057例房颤患者。尽管大多数(75.2%)房颤患者CHADS2评分≥2,但是仅5

杨树森:直接PCI中血栓抽吸新进展及在指南中的地位

直接PCI被公认是STEMI治疗的I类适应证。近年来随着冠状动脉支架和围手术期新强效抗栓药物的应用,PCI治疗的即刻成功率和术后长期疗效进一步提高。然而当冠状动脉内血栓负荷较重时,在介入治疗中血栓易脱落导致微栓塞,引起“无血流”或“慢血流”,与心肌充分复流的患者相比,无复流患者在心肌梗死后更多发生充血性心力衰竭、恶性心律失常和心脏性猝死,在梗死恢复期更多表现为进行性心功能下降。目前认为无复流发生的

Am J Cardiol:右室功能障碍与STEMI患者远期预后不佳相关

意大利一项研究表明,在接受冠脉血运重建的下壁STEMI患者中,右室功能障碍与远期预后恶化具有相关性。术后TIMI血流分级有助于预测右室功能障碍。论文于5月5日在线发表于《美国心脏病学杂志》(Am J Cardiol)。 此项研究共纳入141例行经皮冠脉介入并且右冠脉为梗死相关动脉的下壁STEMI患者。评估再灌注指数与右室功能障碍的相关性。利用TIMI血流、TFC、心肌显影分级(MBG)和ST段正

AHJ:PCI前无他汀预处理与患者转归无关?

    美国一项研究表明,无他汀类药物预处理的经皮冠状动脉介入治疗(PCI)患者数量显著,但与患者院内严重并发症或长期死亡无相关性。研究论文4月7日在线发表于《美国心脏杂志》(American Heart Journal)。     既往研究显示,在行PCI前给予患者他汀类药物与围术期心肌梗死和对比剂肾病(CIN)风险减